Abstract 2357P
Background
Patients with EGFR-mutant non-small cell lung cancer (NSCLC) can derive significant clinical benefit from EGFR tyrosine kinase inhibitor (TKI) therapy, including 3rd generation EGFR TKIs such as osimertinib. However, most patients will experience disease progression with osimertinib, mainly due to acquired mechanisms of resistance. Mutations in the C797 residue in exon 20 are the most frequent EGFR-dependent mechanism of resistance to osimertinib treatment. TRX-221 is an investigational, broad-spectrum, CNS-active, mutant-selective 4th-generation EGFR-TKI (AACR 2023 #4006). Here we report further preclinical data supporting the clinical development of TRX-221 for patients with EGFR-mutant NSCLC.
Methods
Anti-proliferative activity and inhibitory potency of EGFR phosphorylation were determined in Ba/F3 cell lines using CellTiter-Glo® and EGFR AlphaLISA. In vivo antitumor efficacy of TRX-221 was evaluated in subcutaneous patient-derived cell line xenograft model and an intracranial tumor xenograft model.
Results
TRX-221 showed potent inhibitory activity of cell proliferation as well as EGFR phosphorylation in cellular assays driven by EGFR-mutants while sparing activity in EGFR wild-type. In osimertinib-resistant xenograft tumor models harboring EGFR C797S mutant cells, TRX-221 induced significant tumor regression without body weight loss. However, only moderate tumor growth inhibition was observed in an EGFR wild-type CDX model, demonstrating that in vivo efficacy was selective toward mutant EGFR. Furthermore, TRX-221 resulted in substantial intracranial antitumor activity with prolonged survival in an intracranial tumor model. Good correlation between plasma exposure levels and inhibitory effect on EGFR phosphorylation was observed with TRX-221 in a CDX tumor model PK/PD study.
Conclusions
TRX-221 is a potent, broad spectrum, and selective 4th generation EGFR-TKI. TRX-221 demonstrates strong antitumor efficacy in osimertinib-resistant tumor models, and thus has potential to treat patients who have developed resistance to 3rd generation EGFR TKI treatment. Initiation of first-in human clinical trial is expected in Q4 2023.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2325P - Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
Presenter: Rafael Rosell
Session: Poster session 16
2326P - Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy
Presenter: Michele Ghidini
Session: Poster session 16
2327P - The impact of the microenvironment on the intratumoral cellular heterogeneity in colorectal cancer
Presenter: Idan Carmi
Session: Poster session 16
2328P - Alternative molecular mechanisms underpinning breast invasive lobular carcinoma identified by genomics-driven artificial intelligence model
Presenter: Fresia Pareja
Session: Poster session 16
2329P - Evidence for the utility of artificial intelligence and image analysis in Ki-67 quantification in solid tumors
Presenter: Xavier Pichon
Session: Poster session 16
2331P - Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Presenter: Jean Louis Merlin
Session: Poster session 16
2332P - Overall survival in breast cancer patients with HER2-low status single- center experience
Presenter: Joanna Huszno
Session: Poster session 16
2333P - Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancers
Presenter: Anna Karlsson
Session: Poster session 16
2334P - Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster session 16